Le Lézard
Classified in: Health, Science and technology, Business
Subject: FVT

Agrios Global Holdings Ltd. to Present at the Annual Invest Conference in Stuttgart Germany

VANCOUVER, March 15, 2019 /CNW/ - Agrios Global Holdings Ltd. (CSE: AGRO), (OTCQB: AGGHF), (FSE: ØSA WKN-A2N62K) ("Agrios" or the "Company") is pleased to announce it will be presenting at the annual Invest Finance Conference, in Stuttgart Germany, Saturday April 6, 2019.

The Invest Conference will take place April 5th and 6th 2019, at the Stuttgart Landesmesse. Invest Stuttgart is an exclusive annual event dedicated to connecting both publicly traded and private equity firms across all sectors with high net worth individuals, institutional managers, and retail investors. 

Agrios will also be participating in the "Grunes Geld" (Green Money) section, located in Halle EO, Booth # E014.  In addition to exhibiting, Agrios will be presenting, Saturday April 6th, 2019 at 14:30, at the Green Money Forum.

"We are excited to be participating at The Invest Stuttgart Messe, our second event in Germany since listing, as it provides the opportunity for us to speak directly with our many valued shareholders in Germany whom we met during our November 2018 visit" said Chris Kennedy President and CEO of Agrios.

The Company also announces that it has granted 500,000 stock options at a price of C$0.67 to consultants and employees of the Company to purchase an aggregate 500,000 common shares in the capital of the Company. 300,000 of those stock options are exercisable for a term of 5 years at an exercise price of C$0.67 per share and are subject to certain vesting conditions while 200,000 of those stock options are exercisable for a term of 2 years at an exercise price of C$0.67 per share and vest immediately.  All stock options are granted in accordance with the terms of the Company's stock option plan and the policies of the CSE. The stock options granted are also subject to a four-month-and-a-day hold period from the date of grant in accordance with applicable securities laws.

About Agrios Global Holdings Ltd.

Agrios Global Holdings is a data analytics driven agriculture technology and services company advancing the latest innovations in indoor growing science. The Company owns, leases and manages properties and equipment for eco-sustainable agronomy and provides advisory services to support all aspects of aeroponic cultivation in the cannabis sector. Agrios is actively pursuing new opportunities to expand its portfolio of tenant growers and infrastructure assets in strategic licensed jurisdictions. Based in Vancouver, BC. Agrios is managed by a highly accomplished team of experienced industry and capital markets experts who are committed to the growth of the company.

This news release was prepared by management of Agrios, which takes full responsibility for its contents. The Canadian Securities Exchange (" CSE ") has not reviewed and does not accept responsibility for the adequacy of this news release.  Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Agrios' periodic filings with Canadian securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements related to corporate strategy and Agrios' ability to execute such strategy, future developments regarding Agrios' expansion into various markets including numerous states within the United States of America, and into Asia, expected costs of hemp fiber, intended development and sales of hemp products, market demand for hemp products, and the business and operations of Agrios as it relates to the Yunnan Province

Although Agrios has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US Federal laws; change in laws; limited operating history; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. Because of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Agrios disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Agrios does not assume any liability for disclosure relating to any other company mentioned herein.

SOURCE Agrios Global Holdings Ltd.

These press releases may also interest you

at 19:34
Ampio Pharmaceuticals, Inc. today announced that on March 11, 2019, the Company resubmitted a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA) for a confirmatory Phase III clinical trial of its biological drug, Ampiontm,...

at 19:30
The "US Healthcare Advertising Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024" report has been added to ResearchAndMarkets.com's offering. The US healthcare advertising market was worth US$ 66 Billion in 2018...

at 19:30
The "Dental Bone Graft Substitutes and Other Biomaterials Market - South Korea - 2018-2024" report has been added to ResearchAndMarkets.com's offering. The dental biomaterials market is growing at a similar rate to that of dental implants, as the...

at 19:16
The U.S. Food and Drug Administration today approved Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive...

at 19:09
The global magnetic resonance imaging market is expected to reach US$ 7,955.1 Mn in 2025 from US$ 5,913.6 in 2017. The magnetic resonance imaging market is estimated to grow with a CAGR of 3.8% from 2018-2025.Read the full report:...

at 19:09
The global liver treatment market is expected to reach US$ 4,883.5 Mn in 2025 from US$ 3,426.8 in 2017. The liver treatment market is estimated to grow with a CAGR of 4.6% from 2018-2025.Read the full report:...

News published on 15 march 2019 at 18:38 and distributed by: